Literature DB >> 34795157

Protective Effects of Endothelin-2 Expressed in Epithelial Cells on Bleomycin-Induced Pulmonary Fibrosis in Mice.

Aristi Intan Soraya1,2, Yoko Suzuki1, Mitsuru Morimoto3, Chemyong Jay Ko4, Koji Ikeda5, Ken-Ichi Hirata2, Noriaki Emoto1,2.   

Abstract

Initially, endothelin (ET)-2 was described as an endothelium-derived vasoconstrictor. However, accumulating evidence suggests the involvement of ET-2 in non-cardiovascular physiology and disease pathophysiology. The deficiency of ET-2 in mice can be lethal, and such mice exhibit a distinct developmental abnormality in the lungs. Nonetheless, the definite role of ET-2 in the lungs remains unclear. The ET-2 isoform, ET-1, promotes pulmonary fibrosis in mice. Although endothelin receptor antagonists (ERAs) show improvements in bleomycin-induced pulmonary fibrosis in mouse models, clinical trials examining ERAs for pulmonary fibrosis treatment have been unsuccessful, even showing harmful effects in patients. We hypothesized that ET-2, which activates the same receptor as ET-1, plays a distinct role in pulmonary fibrosis. In this study, we showed that ET-2 is expressed in the lung epithelium, and ET-2 deletion in epithelial cells of mice results in the exacerbation of bleomycin-induced pulmonary fibrosis. ET-2 knockdown in lung epithelial cell lines resulted in increased apoptosis mediated via oxidative stress induction. In contrast to the effects of ET-1, which induced fibroblast activation, ET-2 hampered fibroblast activation in primary mouse lung fibroblast cells by inhibiting the TGF-β-SMAD2/3 pathway. Our results demonstrated the divergent roles of ET-1 and ET-2 in pulmonary fibrosis pathophysiology and suggested that ET-2, expressed in epithelial cells, exerts protective effects against the development of pulmonary fibrosis in mice.

Entities:  

Keywords:  endothelin-2; epithelial cells; fibroblast; pulmonary fibrosis

Mesh:

Substances:

Year:  2021        PMID: 34795157      PMCID: PMC8622215     

Source DB:  PubMed          Journal:  Kobe J Med Sci        ISSN: 0023-2513


  32 in total

1.  Myocardial expression of endothelin-2 is altered reciprocally to that of endothelin-1 during ischemia of cardiomyocytes in vitro and during heart failure in vivo.

Authors:  Y Kakinuma; T Miyauchi; T Kobayashi; K Yuki; S Maeda; S Sakai; K Goto; I Yamaguchi
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

Review 2.  Biased signalling: from simple switches to allosteric microprocessors.

Authors:  Jeffrey S Smith; Robert J Lefkowitz; Sudarshan Rajagopal
Journal:  Nat Rev Drug Discov       Date:  2018-01-05       Impact factor: 84.694

3.  β-arrestin deficiency protects against pulmonary fibrosis in mice and prevents fibroblast invasion of extracellular matrix.

Authors:  Alysia Kern Lovgren; Jeffrey J Kovacs; Ting Xie; Erin N Potts; Yuejuan Li; W Michael Foster; Jiurong Liang; Eric B Meltzer; Dianhua Jiang; Robert J Lefkowitz; Paul W Noble
Journal:  Sci Transl Med       Date:  2011-03-16       Impact factor: 17.956

4.  Localization of endothelin receptors in bleomycin-induced pulmonary fibrosis in the rat.

Authors:  Martina Wendel; Anna Petzold; Roland Koslowski; Michael Kasper; Antje Augstein; Lilla Knels; Jörg-Uwe Bleyl; Thea Koch
Journal:  Histochem Cell Biol       Date:  2004-10-05       Impact factor: 4.304

5.  Endothelin-2 is a macrophage chemoattractant: implications for macrophage distribution in tumors.

Authors:  Matthew J Grimshaw; Julia L Wilson; Frances R Balkwill
Journal:  Eur J Immunol       Date:  2002-09       Impact factor: 5.532

6.  Evidence for an expansion-based temporal Shh gradient in specifying vertebrate digit identities.

Authors:  Brian D Harfe; Paul J Scherz; Sahar Nissim; Hua Tian; Andrew P McMahon; Clifford J Tabin
Journal:  Cell       Date:  2004-08-20       Impact factor: 41.582

7.  Characterization of the A549 cell line as a type II pulmonary epithelial cell model for drug metabolism.

Authors:  K A Foster; C G Oster; M M Mayer; M L Avery; K L Audus
Journal:  Exp Cell Res       Date:  1998-09-15       Impact factor: 3.905

8.  A novel peptide, vasoactive intestinal contractor, of a new (endothelin) peptide family. Molecular cloning, expression, and biological activity.

Authors:  K Saida; Y Mitsui; N Ishida
Journal:  J Biol Chem       Date:  1989-09-05       Impact factor: 5.157

9.  Endothelin-converting enzyme-1 gene ablation attenuates pulmonary fibrosis via CGRP-cAMP/EPAC1 pathway.

Authors:  Anggoro Budi Hartopo; Noriaki Emoto; Nicolas Vignon-Zellweger; Yoko Suzuki; Keiko Yagi; Kazuhiko Nakayama; Ken-ichi Hirata
Journal:  Am J Respir Cell Mol Biol       Date:  2013-04       Impact factor: 6.914

10.  Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.

Authors:  Ganesh Raghu; Juergen Behr; Kevin K Brown; Jim J Egan; Steven M Kawut; Kevin R Flaherty; Fernando J Martinez; Steven D Nathan; Athol U Wells; Harold R Collard; Ulrich Costabel; Luca Richeldi; Joao de Andrade; Nasreen Khalil; Lake D Morrison; David J Lederer; Lixin Shao; Xiaoming Li; Patty S Pedersen; A Bruce Montgomery; Jason W Chien; Thomas G O'Riordan
Journal:  Ann Intern Med       Date:  2013-05-07       Impact factor: 25.391

View more
  1 in total

Review 1.  Endothelin and the Cardiovascular System: The Long Journey and Where We Are Going.

Authors:  Andreas Haryono; Risa Ramadhiani; Gusty Rizky Teguh Ryanto; Noriaki Emoto
Journal:  Biology (Basel)       Date:  2022-05-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.